Tecvayli and Darzalex combination shows unprecedented progression-free survival in relapsed/refractory multiple myeloma, ...

Teclistamab-cqyv significantly improves PFS and OS in multiple myeloma patients with 1 to 3 prior therapies, showing a 71% ...

Among patients with relapsed or refractory multiple myeloma, Tecvayli (teclistamab-cqyv) monotherapy was associated with a 71 ...

The MajesTEC-9 trial showed a 40% reduced risk of death and a 71% reduced risk of disease progression or death with ...

Arcellx (ACLX) and Legend Biotech (LEGN) traded higher on Tuesday after the U.S. FDA issued draft guidance on the use of ...

Patients were randomly assigned on a 1:1 basis to receive teclistamab as monotherapy or physician’s choice of ...

Teclistamab plus daratumumab delivers unprecedented progression-free survival benefits over standard of care in ...

The treatment landscape for relapsed and refractory multiple myeloma (RRMM) has changed dramatically over the past decade, resulting in more therapeutic options for various stages of relapse. In a ...

A Prescription Drug User Fee Act target date of July 10, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted the resubmitted Biologics License Application ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. The good news, I guess, is that we have ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this 12-part journey through a disease state ...

LBA-6: Phase 3 randomized study of teclistamab plus daratumumab versus investigator's choice of daratumumab and dexamethasone with either pomalidomide or bortezomib (DPd/DVd) in patients (Pts) with ...